| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2023―Dec―19 |
Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables |
Stefania Barone, Camillo Palmieri, Luca Gallelli, Vincenzo Rania, Angelo Pascarella, Antonio Abatino, et al. (+7) Pietro Antonio Bruno, Alessandro Casarella, Marilisa Pasquale, Lucia Manzo, Giovambattista De Sarro, Antonio Gambardella, Paola Valentino |
| 2 |
[GO] |
2022―Aug―29 |
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic |
Aurora Zanghì, Carlo Avolio, Elisabetta Signoriello, Gianmarco Abbadessa, Maria Cellerino, Diana Ferraro, et al. (+12) Christian Messina, Stefania Barone, Graziella Callari, Elena Tsantes, Patrizia Sola, Paola Valentino, Franco Granella, Francesco Patti, Giacomo Lus, Simona Bonavita, Matilde Inglese, Emanuele D’Amico |
| 3 |
[GO] |
2022―Jul―21 |
Therapeutic Approaches to the Neurologic Manifestations of COVID-19 |
Edith L. Graham, Igor J. Koralnik, Eric M. Liotta |
| 4 |
[GO] |
2021―Dec―03 |
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies |
Fioravante Capone, Matteo Lucchini, Elisabetta Ferraro, Assunta Bianco, Mariagrazia Rossi, Alessandra Cicia, et al. (+8) Antonio Cortese, Alessandro Cruciani, Valeria De Arcangelis, Laura De Giglio, Francesco Motolese, Biagio Sancetta, Massimiliano Mirabella, Vincenzo Di Lazzaro |
| 5 |
[GO] |
2021―Feb―02 |
Potential Risks and Benefits of Multiple Sclerosis Immune Therapies in the COVID-19 Era: Clinical and Immunological Perspectives |
Vikram Bhise, Suhayl Dhib-Jalbut |
|
